Maternal RSV Virus-Like Particle Immunization in Primates

A maternal vaccine tested in pregnant macaques

The paper asks whether vaccinating a mother against RSV can protect her infant before the infant can be immunized, and whether pregnancy itself changes the vaccine response. The team used rhesus macaques because mice are only semi-permissive to RSV and do not reproduce key features of infant lung disease, as the paper notes.

Eleven pregnant macaques were randomly assigned to receive 50 µg of RSV-VLPs (n = 6) or PBS (n = 5) by intramuscular injection at 8 and 15 weeks of gestation, seven weeks apart. After uncomplicated births, infants were nursery-reared with formula because successful breastfeeding could not be quantified. Thirty days after delivery, dams and infants were challenged with 1 × 10⁶ PFU of RSV line 19; adults received intratracheal, intranasal, and conjunctival challenge, while infants received intratracheal challenge only. A separate group of six nonpregnant macaques was immunized and boosted on the same schedule and challenged 14 weeks after the boost to mirror the pregnant timeline.

What the VLP vaccine and antibody titers measure

The vaccine is a virus-like particle: a virus-sized particle that displays RSV antigens in repetitive arrays but does not replicate. Here the particles carry two RSV proteins, a stabilized pre-fusion F protein called UC-3F and the G protein from a subtype A strain, fused to Newcastle disease virus domains that help the particles assemble and release.

The main readouts are reciprocal endpoint IgG titers against pre-fusion F, post-fusion F, and G in plasma and bronchoalveolar lavage fluid (BALF), plus neutralizing antibody (NAb) titers. These are different measures: IgG titers quantify binding antibody, NAb titers quantify the ability to block infection, and BALF samples reflect the lung mucosal compartment rather than blood. The paper also measured antibody-dependent complement deposition (ADCD) and antibody-dependent cellular phagocytosis (ADCP), two Fc-effector functions that describe what antibody-bound targets can trigger beyond neutralization.

Vaccination raised plasma and lung IgG in pregnancy

At 19 weeks of gestation, vaccinated dams had significantly higher plasma IgG against pre-fusion F (P = 0.02), post-fusion F (P = 0.001), and G (P = 0.002) than sham-immunized controls. Pre-fusion F IgG in BALF was also significantly higher in vaccinated animals (P = 0.0003). Within the vaccinated group, pre-fusion F IgG rose from 8 to 19 weeks (P = 0.01) and post-fusion F IgG rose modestly (P = 0.03), while the G protein increase was not significant.

NAb titers rose between 8 and 19 weeks (P < 0.001), and a single dose at 8 weeks was already enough to raise NAb titers at 11 weeks compared with sham animals (P = 0.04). Pre-fusion F IgA did not increase in plasma or BALF. During pregnancy, ADCP rose significantly at 19 weeks (P < 0.05) while ADCD showed only a slight, non-significant increase (P = 0.3).

Vaccinated dams recalled antibody and cleared virus faster

At the time of post-partum challenge, vaccinated dams had higher plasma IgG against pre-fusion F (P = 0.01), post-fusion F (P < 0.001), and G (P = 0.003), and higher plasma NAb titers (P = 0.02) than sham controls. BALF pre-fusion F IgG was only slightly higher at challenge and not significantly different (P = 0.1). After challenge, vaccinated dams mounted IgG recall responses in plasma that peaked at 21 days post-infection and persisted to 26 days, and pre-fusion F IgG also rose in BALF. Sham-immunized controls did not generate recall IgG against pre-fusion F or G, or new NAbs.

Viral load was measured by RT-PCR of the RSV M gene. Peak virus in sham dams occurred at 7–10 days post-infection in nasal swabs and at 3 days in oropharyngeal swabs and BALF. At those peaks, vaccinated dams had lower virus in nasal swabs at 7 days (P = 0.005) and 10 days (P = 0.002) and in oropharyngeal swabs at 3 days (P = 0.0009); BALF virus did not differ significantly. Temperature, respiratory rate, and oxygen saturation also did not differ between groups, so the viral-load reduction was not accompanied by a measurable clinical difference in this cohort.

Infants carried maternal antibody into the lung

Infants from vaccinated dams had higher RSV antibody levels in plasma and lung mucosa at the time of their own challenge, consistent with placental transfer of maternal IgG. The paper reports that these infant antibody levels correlated with reduced viral load, and that infants from vaccinated dams also showed reduced pulmonary eosinophilia.

The correlation analysis used individual infant data points from vaccinated dams, with log-transformed antibody values compared against peak BALF viral load and adjusted for multiple comparisons. That design supports an association between higher transferred antibody and lower peak virus; it does not by itself prove that antibody caused the lower viral load, because the infants were not randomized individually and other maternal factors could differ.

Pregnancy did not blunt the vaccine response

The nonpregnant comparison group was seropositive against pre-fusion F, post-fusion F, and G and had similar pre-study titers to the pregnant vaccinated cohort. After immunization, both groups showed similar increases in pre-fusion F IgG and similar modest increases in G IgG. The difference appeared in post-fusion F and NAb responses: pregnant vaccinated animals had significant rises in post-fusion F IgG (P = 0.03) and NAbs (P = 0.03) after immunization, while nonpregnant animals did not.

After challenge, pregnant vaccinated animals again showed stronger post-fusion F recall (P = 0.02) and NAb responses (P = 0.02), and had significantly higher post-fusion F IgG and NAb levels than nonpregnant vaccinated controls at several time points. These higher responses were associated with lower virus in nasal swabs (5 days, P = 0.05; 7 days, P = 0.004), oropharyngeal swabs (5 days, P = 0.007), and BALF (3 days, P = 0.048). The authors describe the pregnancy effect as exploratory rather than established.

Where the primate evidence stops

The study used 4–6 animals per cohort, a sample size the authors defend as typical for single-sex primate studies but also acknowledge may miss some vaccine-induced responses. The macaques were RSV-experienced before vaccination, so the results describe boosting of pre-existing immunity rather than responses in RSV-naive animals. The vaccine contains pre-fusion F from an RSV A2 strain and was tested against a similar RSV A strain; the paper did not test protection against RSV B, a single third-trimester dose, or whether adding G protein is superior to pre-fusion F alone in macaques. Antigen-specific cellular immunity and immunoglobulin composition were not characterized.

These boundaries matter for reading the infant result: the protection signal comes from antibody transfer in a controlled primate challenge model, not from a human efficacy trial. The paper's own framing is that the data support the protective potential of a VLP-based maternal strategy and that the pregnancy-related differences require expanded studies.

The antibody threshold is the practical question

The most decision-relevant comparison in this paper is not simply that vaccinated infants did better, but that the infant antibody level at challenge tracked with peak viral load. That makes transferred pre-fusion F antibody, measured in both plasma and lung mucosa, the variable to watch when judging whether a maternal RSV VLP strategy is working.

The pregnancy comparison adds a second priority: post-fusion F IgG and NAb responses were higher in pregnant than nonpregnant vaccinated macaques, and that difference coincided with lower virus across nasal, oropharyngeal, and BALF samples. Because the authors call this exploratory and the cohorts were small, the practical reading is that pregnancy did not impair the response in this model and may have amplified selected humoral measures, while the infant antibody–viral load relationship remains the central protective signal to test in larger studies.

Sources used in this answer